Tenon Medical, Inc. Insider Trading Activity

Q: What did Tenon Medical (TNON) report in this Form 4?

An award of 281,872 restricted stock units to CEO, President, and Director Steven Foster on October 13, 2025.

Q: How do the RSUs convert for TNON?

Each RSU represents a contingent right to receive one share of common stock.

Q: What is the vesting schedule for the 281,872 RSUs at TNON?

50% vests on January 1, 2026 and 50% on July 31, 2026.

Q: What ownership form is reported for these TNON RSUs?

The ownership form is reported as Direct.

Q: Who received the TNON RSU grant?

Steven Foster, the company’s CEO, President, and Director.

Tenon Medical (TNON) disclosed a Form 4 for CEO, President, and Director Steven Foster showing a grant of 281,872 restricted stock units on October 13, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tenon Medical (TNON) disclosed a Form 4 for CEO, President, and Director Steven Foster showing a grant of 281,872 restricted stock units on October 13, 2025. Each RSU represents the right to receive one share of Tenon common stock. The filing states a derivative security price of $0.

The award vests in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. The ownership reported for these derivative securities is Direct.

Insider Trade Summary

Grant/Award: 281,872 shares

Grant/Award 1 txn

Insider FOSTER STEVEN M

Role CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	281,872	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 281,872 contracts (Direct)

Footnotes (2)

F1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2. Fifty percent (50%) of the total number of restricted stock units shall vest and automatically convert into shares of common stock of the Issuer (on one-for-one basis) on January 1, 2026 and the remaining fifty percent (50%) shall vest and automatically convert into the shares of common stock of the Issuer (on one-for-one basis) on July 31, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tenon Medical (TNON) report in this Form 4?

An award of 281,872 restricted stock units to CEO, President, and Director Steven Foster on October 13, 2025.

How do the RSUs convert for TNON?

Each RSU represents a contingent right to receive one share of common stock.

What is the vesting schedule for the 281,872 RSUs at TNON?

50% vests on January 1, 2026 and 50% on July 31, 2026.

What price is associated with the RSU derivative security?

The filing lists a derivative security price of $0.

What ownership form is reported for these TNON RSUs?

The ownership form is reported as Direct.

Who received the TNON RSU grant?

Steven Foster, the company’s CEO, President, and Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/15/2025 - 12:00 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

FOSTER STEVEN M

(Last)

(First)

(Middle)

104 COOPER COURT

(Street)

LOS GATOS

95032

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	10/13/2025		A		281,872		⁽²⁾	⁽²⁾	Common Stock	281,872	$0	281,872	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

2. Fifty percent (50%) of the total number of restricted stock units shall vest and automatically convert into shares of common stock of the Issuer (on one-for-one basis) on January 1, 2026 and the remaining fifty percent (50%) shall vest and automatically convert into the shares of common stock of the Issuer (on one-for-one basis) on July 31, 2026.

	/s/ Steven Foster	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR